Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes.
Saved in:
| Title: | Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes. |
|---|---|
| Authors: | Neugebauer R; Division of Research, Kaiser Permanente Northern California, Pleasanton., An J; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena., Dombrowski SK; Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, Pennsylvania., Oshiro C; Center for Integrated Health Care Research, Kaiser Permanente Hawaii, Honolulu., Cassidy-Bushrow A; Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan.; Michigan State University Health Sciences, Detroit.; Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing., Gilliam L; Endocrinology and Internal Medicine, Kaiser Permanente Northern California, South San Francisco., Simonson G; HealthPartners Institute, International Diabetes Center, Minneapolis, Minnesota., Karter AJ; Division of Research, Kaiser Permanente Northern California, Pleasanton., Bergenstal R; HealthPartners Institute, International Diabetes Center, Minneapolis, Minnesota., Finertie H; Division of Research, Kaiser Permanente Northern California, Pleasanton., Yassin MM; Division of Research, Kaiser Permanente Northern California, Pleasanton., Knowlton G; HealthPartners Institute, Minneapolis, Minnesota., Lin SR; Division of Research, Kaiser Permanente Northern California, Pleasanton., Dyer W; Division of Research, Kaiser Permanente Northern California, Pleasanton., Pimentel N; Division of Research, Kaiser Permanente Northern California, Pleasanton., Izadian K; Division of Research, Kaiser Permanente Northern California, Pleasanton., Schmittdiel J; Division of Research, Kaiser Permanente Northern California, Pleasanton., Thomas TW; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California., Hooker SA; HealthPartners Institute, Minneapolis, Minnesota., Nolan MB; HealthPartners Institute, Minneapolis, Minnesota., Wright E; Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, Pennsylvania., Aurora L; Division of Cardiology, Department of Medicine, Henry Ford Health, Detroit, Michigan., Rodriguez LA; Division of Research, Kaiser Permanente Northern California, Pleasanton., Kaur J; Department of Endocrinology, HealthPartners, St Paul, Minnesota., Adams AS; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.; Department of Health Policy, Stanford University School of Medicine, Stanford, California., van der Laan MJ; Division of Biostatistics, School of Public Health, University of California, Berkeley., O'Connor PJ; HealthPartners Institute, Minneapolis, Minnesota. |
| Source: | JAMA network open [JAMA Netw Open] 2025 Oct 01; Vol. 8 (10), pp. e2536100. Date of Electronic Publication: 2025 Oct 01. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
